tiprankstipranks
Incyte Corp (INCY)
NASDAQ:INCY
US Market
Want to see INCY full AI Analyst Report?

Incyte (INCY) Stock Forecast & Price Target

1,914 Followers
See the Price Targets and Ratings of:

INCY Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
7 Buy
9 Hold
1 Sell
Based on 17 analysts giving stock ratings to
Incyte
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

INCY Stock 12 Month Forecast

Average Price Target

$107.43
▲(9.82% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $107.43 with a high forecast of $135.00 and a low forecast of $75.00. The average price target represents a 9.82% change from the last price of $97.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"$59","136":"$136","78.25":"$78.3","97.5":"$97.5","116.75":"$116.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.42857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$107.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,78.25,97.5,116.75,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.3,97.43076923076923,100.56153846153846,103.6923076923077,106.82307692307693,109.95384615384616,113.08461538461538,116.21538461538461,119.34615384615384,122.47692307692307,125.6076923076923,128.73846153846154,131.86923076923077,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.3,95.3098901098901,96.31978021978021,97.32967032967032,98.33956043956044,99.34945054945055,100.35934065934066,101.36923076923077,102.37912087912088,103.38901098901098,104.39890109890109,105.40879120879121,106.41868131868132,{"y":107.42857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.3,92.81538461538462,91.33076923076923,89.84615384615384,88.36153846153846,86.87692307692308,85.3923076923077,83.9076923076923,82.42307692307692,80.93846153846154,79.45384615384616,77.96923076923076,76.48461538461538,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":60.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.31,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$135.00Average Price Target$107.43Lowest Price Target$75.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on INCY
Piper Sandler
Piper Sandler
$110
Buy
12.45%
Upside
Reiterated
04/24/26
Incyte (INCY) Gets a Buy from Piper Sandler
Barclays Analyst forecast on INCY
Barclays
Barclays
$117
Buy
19.61%
Upside
Assigned
04/20/26
Analysts Offer Insights on Healthcare Companies: Immatics (NASDAQ: IMTX), Incyte (NASDAQ: INCY) and Perspective Therapeutics (NYSE MKT: CATX)
Bank of America Securities Analyst forecast on INCY
Bank of America Securities
Bank of America Securities
Buy
Reiterated
04/16/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), MiMedx Group (NASDAQ: MDXG) and QuidelOrtho (NASDAQ: QDEL)
H.C. Wainwright Analyst forecast on INCY
H.C. Wainwright
H.C. Wainwright
$135
Buy
38.01%
Upside
Reiterated
04/15/26
Bullish View on Povorcitinib’s Broad HS Adoption and Manageable JAK Safety Supports $135 Target
RBC Capital Analyst forecast on INCY
RBC Capital
RBC Capital
$92$95
Hold
-2.88%
Downside
Reiterated
04/07/26
Incyte price target raised to $95 from $92 at RBC CapitalIncyte price target raised to $95 from $92 at RBC Capital
Wells Fargo Analyst forecast on INCY
Wells Fargo
Wells Fargo
$101
Hold
3.25%
Upside
Assigned
04/02/26
Incyte (INCY) Receives a Hold from Wells Fargo
TD Cowen Analyst forecast on INCY
TD Cowen
TD Cowen
$123
Buy
25.74%
Upside
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Veradigm (Other OTC: MDRX)
Stifel Nicolaus Analyst forecast on INCY
Stifel Nicolaus
Stifel Nicolaus
$120
Buy
22.67%
Upside
Reiterated
03/30/26
Stifel Nicolaus Keeps Their Buy Rating on Incyte (INCY)
William Blair Analyst forecast on INCY
William Blair
William Blair
Hold
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Lipocine (NASDAQ: LPCN), Viridian Therapeutics (NASDAQ: VRDN) and Incyte (NASDAQ: INCY)
Guggenheim Analyst forecast on INCY
Guggenheim
Guggenheim
$130
Buy
32.90%
Upside
Reiterated
03/29/26
Guggenheim Sticks to Their Buy Rating for Incyte (INCY)
UBS
$104$94
Hold
-3.91%
Downside
Assigned
03/25/26
Incyte price target lowered to $94 from $104 at UBSIncyte price target lowered to $94 from $104 at UBS
BMO Capital Analyst forecast on INCY
BMO Capital
BMO Capital
$75
Sell
-23.33%
Downside
Reiterated
03/23/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Incyte (NASDAQ: INCY)
Truist Financial Analyst forecast on INCY
Truist Financial
Truist Financial
Hold
Reiterated
03/18/26
Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Hinge Health, Inc. Class A (NYSE: HNGE) and Healthequity (NASDAQ: HQY)
Jefferies
$94
Hold
-3.91%
Downside
Downgraded
03/15/26
Incyte downgraded to Hold from Buy at JefferiesIncyte downgraded to Hold from Buy at Jefferies
Evercore ISI Analyst forecast on INCY
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$73$110
Hold
12.45%
Upside
Reiterated
03/05/26
Evercore ISI Remains a Hold on Incyte (INCY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on INCY
Piper Sandler
Piper Sandler
$110
Buy
12.45%
Upside
Reiterated
04/24/26
Incyte (INCY) Gets a Buy from Piper Sandler
Barclays Analyst forecast on INCY
Barclays
Barclays
$117
Buy
19.61%
Upside
Assigned
04/20/26
Analysts Offer Insights on Healthcare Companies: Immatics (NASDAQ: IMTX), Incyte (NASDAQ: INCY) and Perspective Therapeutics (NYSE MKT: CATX)
Bank of America Securities Analyst forecast on INCY
Bank of America Securities
Bank of America Securities
Buy
Reiterated
04/16/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), MiMedx Group (NASDAQ: MDXG) and QuidelOrtho (NASDAQ: QDEL)
H.C. Wainwright Analyst forecast on INCY
H.C. Wainwright
H.C. Wainwright
$135
Buy
38.01%
Upside
Reiterated
04/15/26
Bullish View on Povorcitinib’s Broad HS Adoption and Manageable JAK Safety Supports $135 Target
RBC Capital Analyst forecast on INCY
RBC Capital
RBC Capital
$92$95
Hold
-2.88%
Downside
Reiterated
04/07/26
Incyte price target raised to $95 from $92 at RBC CapitalIncyte price target raised to $95 from $92 at RBC Capital
Wells Fargo Analyst forecast on INCY
Wells Fargo
Wells Fargo
$101
Hold
3.25%
Upside
Assigned
04/02/26
Incyte (INCY) Receives a Hold from Wells Fargo
TD Cowen Analyst forecast on INCY
TD Cowen
TD Cowen
$123
Buy
25.74%
Upside
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Veradigm (Other OTC: MDRX)
Stifel Nicolaus Analyst forecast on INCY
Stifel Nicolaus
Stifel Nicolaus
$120
Buy
22.67%
Upside
Reiterated
03/30/26
Stifel Nicolaus Keeps Their Buy Rating on Incyte (INCY)
William Blair Analyst forecast on INCY
William Blair
William Blair
Hold
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Lipocine (NASDAQ: LPCN), Viridian Therapeutics (NASDAQ: VRDN) and Incyte (NASDAQ: INCY)
Guggenheim Analyst forecast on INCY
Guggenheim
Guggenheim
$130
Buy
32.90%
Upside
Reiterated
03/29/26
Guggenheim Sticks to Their Buy Rating for Incyte (INCY)
UBS
$104$94
Hold
-3.91%
Downside
Assigned
03/25/26
Incyte price target lowered to $94 from $104 at UBSIncyte price target lowered to $94 from $104 at UBS
BMO Capital Analyst forecast on INCY
BMO Capital
BMO Capital
$75
Sell
-23.33%
Downside
Reiterated
03/23/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Incyte (NASDAQ: INCY)
Truist Financial Analyst forecast on INCY
Truist Financial
Truist Financial
Hold
Reiterated
03/18/26
Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Hinge Health, Inc. Class A (NYSE: HNGE) and Healthequity (NASDAQ: HQY)
Jefferies
$94
Hold
-3.91%
Downside
Downgraded
03/15/26
Incyte downgraded to Hold from Buy at JefferiesIncyte downgraded to Hold from Buy at Jefferies
Evercore ISI Analyst forecast on INCY
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$73$110
Hold
12.45%
Upside
Reiterated
03/05/26
Evercore ISI Remains a Hold on Incyte (INCY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

3 Months
xxx
Success Rate
15/22 ratings generated profit
68%
Average Return
+6.38%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +6.38% per trade.
1 Year
Success Rate
15/15 ratings generated profit
100%
Average Return
+26.63%
Copying David Lebowitz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +26.63% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
100%
Average Return
+47.39%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +47.39% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INCY Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
25
21
22
26
26
Hold
30
25
23
22
15
Sell
2
4
4
4
2
Strong Sell
0
0
0
0
0
total
57
50
49
52
43
In the current month, INCY has received 26 Buy Ratings, 15 Hold Ratings, and 2 Sell Ratings. INCY average Analyst price target in the past 3 months is 107.43.
Each month's total comprises the sum of three months' worth of ratings.

INCY Financial Forecast

INCY Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

INCY Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

INCY Stock Forecast FAQ

What is INCY’s average 12-month price target, according to analysts?
Based on analyst ratings, Incyte Corp’s 12-month average price target is 107.43.
    What is INCY’s upside potential, based on the analysts’ average price target?
    Incyte Corp has 9.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is INCY a Buy, Sell or Hold?
          Incyte Corp has a consensus rating of Moderate Buy which is based on 7 buy ratings, 9 hold ratings and 1 sell ratings.
            What is Incyte Corp’s price target?
            The average price target for Incyte Corp is 107.43. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $135.00 ,the lowest forecast is $75.00. The average price target represents 9.82% Increase from the current price of $97.82.
              What do analysts say about Incyte Corp?
              Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of INCY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.